CTXR — Citius Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Citius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Citius Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Citius Pharmaceuticals Announces Closing Of $15 Mln Registered Direct Offering
Brief: Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
Brief: Citius Pharmaceuticals Announces Addition Of City Of Hope To UMN's Phase 1 Trial Of LYMPHIR
Brief: Citius Pharmaceuticals Announces FDA Acceptance Of The BLA Resubmission Of LYMPHIR™
Brief: Nasdaq Granted Citius Pharmaceuticals' Request For Extension To Evidence Compliance Listing Requirement
Brief: Citius Pharmaceuticals Announces Filing Of Form S-3 Shelf Registration Statement To Replace Expiring Prior Shelf Registration
Brief: Citius Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 Million
Citius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Citius Pharmaceuticals Inc expected to post earnings of 13 cents a share - Earnings Preview
Brief: Citius Pharmaceuticals Announces Nomination Of Pharmaceutical Executive Robert J. Smith To Its Board Of Directors
Brief: Citius Pharmaceuticals Reports FY2023 Financial Results
Brief: Citius Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Trial Of Its Mino-Lok® Therapeutic To Salvage Catheters
Citius Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Citius Pharmaceuticals Inc expected to post a loss of 2 cents a share - Earnings Preview
Brief: Citius Pharmaceuticals Announces Publication In Frontiers Of Immunology Of Positive Results From Solid Tumor Study Of Lymphir In Combination With Checkpoint Inhibitor
Brief: Citius Pharma's Unit To Merge With Tenx Keane Acquisition To Form Publicly Listed Citius Oncology
Brief: Citius Pharmaceuticals Says On September 12, Co Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq